Table 2.

Markers of bone turnover and bone regulators

	All patients			Patients without bone metastases
	Cancer Cachexia (n = 31)	Cancer (n = 21)	p	Cancer Cachexia (n = 28)	Cancer (n = 16)	p
CTX, ng/mL	0.38 (0.3–0.6)	0.31 (0.2–0.4)	0.08	0.38 (0.3–0.5)	0.27 (0.2–0.4)	0.03
Ocn ng/ml a	14.2 (± 5.5)	16.4 (± 5.3)	0.2	14.3 (± 5.6)	16.4 (± 4.4)	0.2
CTX/Ocn ratio > 0.022, n (%)	21 (67.7)	6 (28.6)	0.006	19 (67.9)	3 (18.8)	0.002
PINP, μg/L	32 (23–39)	27.5 (22–41)	0.6	31.9 (23–38)	26.1 (21–38)	0.5
CTX/PINP ratio > 0.011, n (%)	19 (61.3)	8 (38.1)	0,1	17 (60.7)	5 (31.3)	0.06
Corrected Ca, mmol/L	2.45 (2.4–2.6)	2.35 (2.3–2.4)	0.002	2.43 (2.4–2.5)	2.33 (2.3–2.4)	0.001
Phosphate, mg/dL	4.2 (4–4.4)	4.3 (4.2–4.6)	0.09	4.2 (4–4.4)	4.4 (4.2–4.6)	0.1
PTH, pg/mL	24.1 (18–34)	27 (23–32)	0.5	24.4 (19–34)	26.6 (23–32)	0.7
25(OH)D, ng/mL	14.4 (8–22)	13 (8–21)	0.7	15.1 (8–22)	13 (9–21)	0.8
TSH, μU/mL	1.7 (1.2–3.4)	1.3 (0.7–1.9)	0.03	1.7 (1–3.3)	1.2 (0.6–1.7)	0.02

Abbreviations: CTX carboxy terminal telopeptide of collagen type I, Ocn osteocalcin, PINP procollagen type I N-terminal propeptides, 25(OH)D 25-hydroxy vitamin D

- All variables are expressed as median and interquartile range (25-75th percentile), except for Ocn ^a(mean ± SD)